Atlas Trials

St. Petersburg Research Institute of Vaccines and Sera

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch St. Petersburg Research Institute of Vaccines and Sera

RecordFirmDate
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older (NCT05726084)St. Petersburg Research Institute of Vaccines and Sera2022-10-24
Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children (NCT05739474)St. Petersburg Research Institute of Vaccines and Sera2022-01-19
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. (NCT05156723)St. Petersburg Research Institute of Vaccines and Sera2021-07-19
Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra (NCT05308212)St. Petersburg Research Institute of Vaccines and Sera2021-03-04
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old (NCT05470582)St. Petersburg Research Institute of Vaccines and Sera2021-02-16
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years (NCT05312294)St. Petersburg Research Institute of Vaccines and Sera2020-12-07
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine (NCT05869201)St. Petersburg Research Institute of Vaccines and Sera2020-10-06
The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old (NCT05089123)St. Petersburg Research Institute of Vaccines and Sera2020-03-03
Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers (NCT05398562)St. Petersburg Research Institute of Vaccines and Sera2020-02-13
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years. (NCT05317767)St. Petersburg Research Institute of Vaccines and Sera2020-02-10
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women (NCT05457894)St. Petersburg Research Institute of Vaccines and Sera2020-01-23
Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b (NCT05401305)St. Petersburg Research Institute of Vaccines and Sera2020-01-14
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers (NCT05152017)St. Petersburg Research Institute of Vaccines and Sera2019-11-16
Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA (NCT05297994)St. Petersburg Research Institute of Vaccines and Sera2016-10-24
The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years (NCT05126979)St. Petersburg Research Institute of Vaccines and Sera2016-03-09

Track St. Petersburg Research Institute of Vaccines and Sera automatically

Every clearance here is in the API, with alerts when new ones post.